Physician profile
Omar Taha
NPI 1639590417
$445.84
in general payments reported to CMS, 2019-2025
10 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.44 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $227.90 | 2025 | |
| Abbvie INC. | $29.98 | 2025 | |
| Pfizer INC. | $29.32 | 2025 | |
| Janssen Biotech, INC. | $27.14 | 2025 | Darzalex, Tecvayli |
| Genentech USA, INC. | $26.20 | 2025 | Itovebi |
| Incyte Corporation | $23.76 | 2025 | Niktimvo, Jakafi |
| Lilly USA, LLC | $21.41 | 2025 | Verzenio, Jaypirca |
| Caris Mpi, INC. | $20.73 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $19.74 | 2025 | Lynparza, Keytruda Qlex, Keytruda |
| Deciphera Pharmaceuticals INC. | $19.66 | 2025 | Romvimza, Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.